Systemic Sclerosis clinical trials at UCSF
3 in progress, 2 open to eligible people
Systemic sclerosis is an autoimmune disease that causes skin to thicken and organs to scar. UCSF is studying a phase 1 B-cell therapy to check safety and drug levels. UCSF is also testing a cell therapy for diffuse skin disease to study effect and safety.
FT819 in B-cell Mediated Autoimmune Disease
open to eligible people ages 12-70
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
San Francisco, California and other locations
Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
open to eligible people ages 18-70
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
San Francisco, California and other locations
Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Sorry, in progress, not accepting new patients
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
San Francisco, California and other locations
Our lead scientists for Systemic Sclerosis research studies include Emily von Scheven.
Last updated: